# Diabetes Remote Intervention to improVe Use of Evidence-based Medications

Study · id `cardio:ct-nct06046560` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06046560](<https://clinicaltrials.gov/study/NCT06046560>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06046560

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT06046560. Randomized; no masking; primary purpose prevention. Start 2021-03-22 (actual); primary completion 2023-07-25 (actual). Results posted on 2024-10-23.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT06046560, source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)
- Started: 2021-03-22 (actual) (ClinicalTrials.gov record NCT06046560, source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)
- Primary completion: 2023-07-25 (actual) (ClinicalTrials.gov record NCT06046560, source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)
- Completion: 2023-07-25 (actual) (ClinicalTrials.gov record NCT06046560, source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)
- Results first posted: 2024-10-23 (ClinicalTrials.gov record NCT06046560, source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06046560, source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06046560-2024-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Diabetes Remote Intervention to improVe Use of Evidence-based Medications
- Acronym: DRIVE
- Condition: Cardiovascular Diseases
- Condition: Diabetes
- Intervention (Drug): SGLT2 inhibitor, GLP-1 RA
- Intervention (Behavioral): Education-First
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial (`cardio:pubmed-38583146`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk (`cardio:pubmed-41610902`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: aa2ee4b4c844fdc8f93da9b1479537fe119e5acb586d517e9700c75b1a6c4316
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
